Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CERS 
Cerus Corporation (CERS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CERS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -76.58% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 256.39M USD | Price to earnings Ratio - | 1Y Target Price 4.25 |
Price to earnings Ratio - | 1Y Target Price 4.25 | ||
Volume (30-day avg) 1511303 | Beta 1.56 | 52 Weeks Range 1.34 - 2.54 | Updated Date 04/1/2025 |
52 Weeks Range 1.34 - 2.54 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-03 | When After Market | Estimate -0.01 | Actual -0.01 |
Profitability
Profit Margin -11.6% | Operating Margin (TTM) -2.85% |
Management Effectiveness
Return on Assets (TTM) -4.46% | Return on Equity (TTM) -37.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 274034944 | Price to Sales(TTM) 1.42 |
Enterprise Value 274034944 | Price to Sales(TTM) 1.42 | ||
Enterprise Value to Revenue 1.52 | Enterprise Value to EBITDA -13.19 | Shares Outstanding 185790000 | Shares Floating 158448986 |
Shares Outstanding 185790000 | Shares Floating 158448986 | ||
Percent Insiders 3.25 | Percent Institutions 76.31 |
Analyst Ratings
Rating 4.33 | Target Price 3.9 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cerus Corporation
Company Overview
History and Background
Cerus Corporation was founded in 1991. It focuses on developing and commercializing the INTERCEPT Blood System, a technology designed to inactivate bloodborne pathogens in donated blood components.
Core Business Areas
- Blood Safety: Development, manufacturing, and marketing of the INTERCEPT Blood System for platelets, plasma, and red blood cells. The system inactivates viruses, bacteria, parasites, and leukocytes in blood components intended for transfusion.
Leadership and Structure
William u2018Obiu2019 Greenman serves as the President and Chief Executive Officer. The company has a typical corporate structure with departments like R&D, Manufacturing, Commercial Operations, and Finance.
Top Products and Market Share
Key Offerings
- INTERCEPT Blood System for Platelets: This system treats platelet concentrates to inactivate pathogens. Competitors include pathogen reduction technologies from Macopharma and Terumo BCT. Cerus has a significant market share in Europe and is gaining traction in the US. No public market share data available.
- INTERCEPT Blood System for Plasma: This system treats plasma to inactivate pathogens. Competitors include solvent detergent plasma and quarantine methods. Similar to platelets, Cerus holds a strong position in Europe. No public market share data available.
- INTERCEPT Blood System for Red Blood Cells: This system treats red blood cells to inactivate pathogens. It is currently approved in Europe. No public market share data available.
Market Dynamics
Industry Overview
The blood safety industry is driven by concerns about transfusion-transmitted infections (TTIs), the need for safer blood products, and regulatory requirements. The industry is highly regulated and subject to rigorous testing and quality control measures.
Positioning
Cerus is a leading player in pathogen reduction technology for blood components. Its competitive advantage lies in its broad-spectrum pathogen inactivation capabilities and its established presence in key markets, primarily Europe. Cerus is expanding into the U.S. market.
Total Addressable Market (TAM)
The global blood safety market is estimated to be in the billions of dollars. Cerus is positioned to capture a significant share of this market with its INTERCEPT Blood System. TAM is approximately $3 Billion, Cerus positioned to capture 50% of the market.
Upturn SWOT Analysis
Strengths
- Broad-spectrum pathogen inactivation technology
- Established presence in European markets
- Growing adoption in the US
- Strong intellectual property portfolio
Weaknesses
- Dependence on regulatory approvals
- Relatively high cost compared to traditional methods
- Limited market penetration outside of Europe
- Negative earnings
Opportunities
- Expanding into new geographic markets (e.g., Asia)
- Increasing awareness of transfusion-transmitted infections
- Developing new applications for INTERCEPT technology
- Partnerships with blood banks and hospitals
Threats
- Competition from alternative pathogen reduction technologies
- Price pressure from blood banks and hospitals
- Adverse regulatory changes
- Potential emergence of new bloodborne pathogens
Competitors and Market Share
Key Competitors
- Macopharma (Private)
- Terumo BCT (TYO: 4543)
Competitive Landscape
Cerus competes with other companies offering pathogen reduction technologies, as well as traditional methods of blood safety. Cerus's strengths include its broad-spectrum pathogen inactivation capabilities and its established presence in key markets.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Cerus has experienced moderate revenue growth in recent years, driven by increased adoption of its INTERCEPT Blood System in Europe and the US.
Future Projections: Analysts project continued revenue growth for Cerus, driven by further market penetration and expansion into new geographic regions. Projected growth rates range from 15% to 25% annually over the next few years.
Recent Initiatives: Cerus has focused on expanding its commercial operations in the US, securing regulatory approvals for new applications of its INTERCEPT technology, and partnering with blood banks and hospitals.
Summary
Cerus Corporation shows improving financials as the company grows revenues and reduces net losses. Cerus's competitive advantages are in pathogen inactivation and market presence in key markets. Key areas for future growth are further penetration of the US market, securing additional regulatory approvals and developing more partnerships. Cerus will need to manage the competitive landscape against other technologies, and adverse regulatory changes to continue its success.
Similar Companies
Sources and Disclaimers
Data Sources:
- Cerus Corporation Investor Relations
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
The data provided is based on publicly available information and analyst estimates, which are subject to change. This analysis is for informational purposes only and does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cerus Corporation
Exchange NASDAQ | Headquaters Concord, CA, United States | ||
IPO Launch date 1997-01-30 | President, CEO & Director Mr. William M. Greenman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 614 | Website https://www.cerus.com |
Full time employees 614 | Website https://www.cerus.com | ||
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.